natgillin/translations-raw huggingface dataset:
(tablet core) lactose monohydrate (see section 2 ‘Olanzapine contains lactose’), maize starch, preglatinised maize starch, crospovidone type A, magnesium stearate and (tablet coating) polyvinyl alcohol, titanium dioxide (E171), talc (E553b), soya lecithin (E322) (see section 2 ‘Olanzapine Mylan contains soya lecithin’), xanthan gum (E415).
(jezgra tablete) laktoza hidrat (pogledajte 2. odjeljak „Olanzapine sadrži laktozu”), kukuruzni škrob, prethodno gelirani kukuruzni škrob, krospovidon tipa A, magnezijev stearat i (ovojnica tablete) polivinilni alkohol, titanijev dioksid (E171), talk (E553b), sojin lecitin (E322) (pogledajte 2. odjeljak „Olanzapine Mylan sadrži sojin lecitin”), ksantanska guma (E415).
(tablet core) lactose monohydrate, hyprolose, crospovidone, microcrystalline cellulose, magnesium stearate and
(jezgra tablete) laktoza hidrat, hiproloza, krospovidon, mikrokristalična celuloza, magnezijev stearat i
(tablet)
(tableta)
(tacrolimus 0.5 mg single dose +
(takrolimus pojedinačna doza od
(tenofovir 300 mg daily + Victrelis
(tenofovir 300 mg na dan +
(The complete SmPC will be provided as a separate document in the medicine pack)
(potpuni Sažetak opisa svojstava lijeka bit će priložen kao zaseban dokument u pakiranju lijeka)
(These can affect 1 to 10 in every 100 people taking Hepsera)
(pojavljuju se u od 1 do 10 pacijenata na svakih 100 ljudi koji uzimaju Hepseru)
(These can affect less than 1 in 10,000 people taking Hepsera)
(pojavljuju se u manje od 1 na 10 000 ljudi koji uzimaju Hepseru)
(These can affect more than 10 in every 100 people taking Hepsera)
(pojavljuju se u više od 10 pacijenata na svakih 100 ljudi koji uzimaju Hepseru)
(These may affect more than 1 in 10 people) infections of the airways, such as coughs and colds (nasopharyngitis, upper respiratory tract infection)
(Mogu se javiti u više od 1 na 10 osoba) infekcije dišnih putova, kao što su kašalj i prehlada (nazofaringitis, infekcija gornjih dišnih putova)
(These may affect up to 1 in 1,000 people)
(mogu se javiti u do 1 na 1000 osoba)
(These may affect up to 1 in 1,000 people)
(mogu se javiti u najviše 1 na 1000 osoba)
(These may affect up to 1 in 10 people)
(Mogu se javiti u manje od 1 na 10 osoba)
(To be completed by physician)
(Ispunjava liječnik)
(To be displayed only on the inner lid of the intermediate carton of multipack)
(Navesti na unutrašnjosti poklopca unutarnje kutije višestrukog pakiranja)
(To be displayed only on the inner lid of the outer carton of multipack)
(Navesti na unutrašnjosti poklopca vanjske kutije višestrukog pakiranja)
(To be displayed only on the inner lid of the outer carton of unit pack)
(Navesti na unutrašnjosti poklopca vanjske kutije jediničnog pakiranja)
(To open, lift here and pull) CARTON HAS BEEN OPENED
(Želite li otvoriti, ovdje podignite i povucite) KUTIJA JE BILA OTVARANA
(TPC)
liječnika (TIL)
(TPV/r 250/200 mg BID) (TPV/r 750/100 mg BID)
(TPV/r 750/100 mg BID)
(Trading as Glaxo Wellcome Operations) Harmire Road
(posluje kao Glaxo Wellcome Operations) Harmire Road
(trading as Glaxo Wellcome Operations) Priory Street
(posluje kao Glaxo Wellcome Operations) Priory Street
(trading as GlaxoWellcome Operations) Harmire Road
(posluje kao Glaxo Wellcome Operations) Harmire Road
(trading as GlaxoWellcome Operations) Harmire Road
(posluje kao GlaxoWellcome Operations) Harmire Road
(U/L x Day)
(U/l x dan)
(UGT induction)
(UGT indukcija)
(UGT inhibition)
(UGT inhibicija)
(UGT1A1 induction)
(indukcija CYP3A4 enzima)
(UGT1A1 induction)
imeprevir/efavirenz
(unboosted saquinavir
Klaritromicin (sakvinavir/ritonavir)
(unboosted saquinavir)
(nepojačani sakvinavir 1200 mg triput na dan)
(unboosted saquinavir)
mogu mijenjati.
(uncommon - may affect up to 1 in 100 people)
(manje često – mogu se javiti u manje od 1 na 100 osoba)
(Uncommon – may affect up to 1 in 100 people)
(Manje često - mogu se javiti u manje od 1 na 100 osoba)
(unit dose)
(jedinična doza)
(unit dose)
pakiranja
(unit dose)
pakiranje)
(unit dose) (multipack)
(jedinična doza)
(unit dose) (multipack)
pakiranja
(unit dose) 56 tablets
56 tableta
(unit dose) 98 x 1 tablet (unit dose)
98 x 1 tablet (pojedinačno pakiranje)
(unit dose) 98 x 1 tablet (unit dose)
98 x 1 tableta
(unspecified)
mjestu primjene
(used with outer carton of 2 sets of 3 constituents)
(koristi se s vanjskim pakiranjem od 2 kompleta s 3 sastojka)
(Vulvo) vaginal fungal infection
(vulvo)vaginalne gljivične infekcije
(w) Censored results at time of cross-over
(w) Cenzurirani rezultati u vrijeme prelaska u drugu skupinu
(Week 16)
(16. tjedan)
(week 16)
Infliksimab (98. tjedan)
(Week 24)
(24. tjedan)
(week 24)
Infliksimab (24. tjedan)
(week 24)
Infliksimab (54. tjedan)
(Week 54)
(54. tjedan)
(week 54)
Randomizirani bolesnici
(Week 98)
(98. tjedan)
(week 98)
Placebo (24. tjedan)
(when used
(kada se
(With a Blue Box - Not for co-packaging with the Altera Nebuliser Handset)
(S plavim okvirom – ne pakira se zajedno s ručnim atomizatorom Altera)
(WITHOUT BLUE BOX)
(BEZ PLAVOG OKVIRA)
(WITHOUT BLUEBOX)
(BEZ PLAVOG OKVIRA)
(x 0.85 for female patients)
(x 0,85 za bolesnice)
(x) Unstratified log-rank test for PFS and Chi-squared test for Overall Response Rate.
(x) Nestratificirani log-rang test za PFS i hi-kvadrat test za stopu ukupnog odgovora na liječenje.
(y) As of December 30, 2010, a total of 549 patients were evaluable for PFS and 439 patients were evaluable for overall response rate.
(y) Od 30. prosinca 2010. na PFS se moglo analizirati ukupno 549, a na ukupan odgovor na liječenje 439 bolesnika.
(~12.8µg/kg) 1
(~12,8 µg/kg) 1
(~17.6µg/kg) 1
(~17,6 µg/kg) 1
(~25.6µg/kg) 1
(~25,6 µg/kg) 1
(~27.2µg/kg) 1
(~27,2 µg/kg) 1
(~36µg/kg) 1
(~36 µg/kg) 1
(~38.4µg/kg) 1
(~38,4 µg/kg) 1
(~44.8µg/kg) 1
(~44,8 µg/kg) 1
(~51.2µg/kg) 1
(~51,2 µg/kg) 1
(~64µg/kg) 1
(~64 µg/kg) 1
(µgh/ml)
(mikrogramh/ml)
(↑ digoxin from probable inhibition of
(↑digoksina zbog vjerojatne inhibicije
(−2.79, −1.35)
Na 151 145 108 108
(≤600,000 IU/ml)
41,4 (63/152) 31,2; 51,7
(≤600,000 IU/ml)
63,5 (61/96)
(≤600,000 IU/ml)
Veliko virusno opterećenje (> 600 000 IU/ml)
(≥ 1/1,000 to
(≥ 1/1000 i
(≥ 1/100 to
(≥ 1/100 i
(≥ 1/1000 to < 1/100)
(≥ 1/1000 i < 1/100);
(≥ 12 to < 17 years old) who participated in Study 206.
13 adolescenata s CF (u dobi ≥ 12 do < 17 godina) koji su sudjelovali u Ispitivanju 206.
(≥1/10,000 to
Rijetko (≥1/10 000 i <1/1000)
( 0.15 µg/ml)
( 0,15 µg/ml)
+ + change in the ratio of CD4 /CD8 in cerebrospinal fluid pre- and post-vedolizumab administration in healthy human volunteers.
+ + promjene u omjeru CD4 /CD8 u cerebrospinalnoj tekućini prije i nakon primjene vedolizumaba kod zdravih ljudskih dobrovoljaca.
+ 1 bottle adapter
1 nastavak za bočicu
+ 1 calibrated dropper
1 kalibrirana kapaljka
+ 1 injection needle 4 pre-filled syringes
štrcaljka + 1 igla
+ 1 matrix
bočica + 1 matrica
+ 1 ml solvent
1 ml praha+ 1 ml otapala
+ 1 syringe
životinja
+ 1 syringe plunger rod + 1 vial adapter +1 venipuncture set + 4 swabs
1 napunjena štrcaljka + 1 potisni klip štrcaljke +
+ 1 syringe plunger rod + 1 vial adapter+1 venipuncture set + 4 swabs + 2 plasters
1 nastavak za bočicu + 1 set za venepunkciju + 4 tupfera + 2 flastera
+ 1 venipuncture set
+ 1 set za venepunkciju
+ 1 vial (solvent) + 1 injection syringe + 1 needle +
+ 1 bočica (otapalo) + 1 štrcaljka za injekciju + 1 igla
+ 10 needles
+ 10 igala
+ 2 cleansing swabs
+ 2 tupfera za čišćenje
+ 2 needles
+ 2 igle
+ 2 syringes
+ 2 brizgalice
+ 2 syringes
+ 2 štrcaljke
+ 2 units
+ 2 jedinice
+ 20 needles
+ 20 igala
+ 24 cleansing swabs
12 igala za injekciju + 24 tupfera za čišćenje
+ 24 cleansing swabs
12 igala za injekciju+ 24 tupfera za čišćenje
+ 25 vials solvent
+ 25 bočica otapala
+ 4 injection needles
štrcaljke + 4 igle
+ 4 swabs
4 tupfera
+ 4 units
+ 4 jedinice
+ 50 vials solvent
+ 50 bočica otapala
+ 6 plungers
+ 6 klipova
+ 6 units
+ 6 jedinica
+ 7 x 20 mg)
mg + 7 x 15 mg + 7 x 20 mg)
+ 8 cleansing swabs
+ 8 tupfera za čišćenje
+ 8 units
+ 8 jedinica
+ and CD8
+ i CD8
+ ASA
+ ASK
+ Based on LOCF with the last on-drug observation carried forward.
+ Na temelju LOCF sa zadnjim zapažanjem na lijeku prenesenim dalje.
+ BR N=682
+ BR N = 682
+ carboplatin (N=521)
+ karboplatin (N = 521)
+ carboplatin (N=531)
+ karboplatin (N = 531)
+ Denotes adverse reactions that have been reported in association with a fatal outcome.
+ Označava nuspojave povezane sa smrtnim ishodom.
+ Denotes adverse reactions that have been reported in association with a fatal outcome.
+ Označava prijavljene nuspojave povezane sa smrtnim ishodom.
+ DMAR D
+ DMARD
+ docetaxel n=402
+ docetaksel n=402
+ docetaxel n=406
+ docetaksel n=406
+ Event rates based on Kaplan-Meier estimates at 3 years.
+ Učestalost događaja temeljem Kaplan-Meierove procjene tijekom tri godine.
+ Exenatide dose was 5 mcg twice daily for first 4 weeks and 10 mcg twice daily thereafter
+ Doza eksenatida iznosila je 5 µg dvaput na dan tijekom prva 4 tjedna, a nakon toga 10 µg dvaput na dan
+ For each term, the frequency count was based on ADRs of all grades.
+ za svaki pojam učestalost se temeljila na nuspojavama na lijek svih stupnjeva.
+ For each term, the frequency count was based on ADRs of all grades.
+ Za svaki pojam učestalost se temeljila na nuspojavama svih stupnjeva.
+ frequency of acquired resistance > 50 % in some Member States
+ Učestalost stečene rezistencije je >50% u nekim državama članicama.
+ Glimepiride 4 mg daily
4 mg na dan
+ insulin
+ inzulin
+ interferon alfa-2b 3 MIU/m2 3 times a week
+ interferon alfa-2b 3 MIU/m2 3 puta na tjedan
+ interferon alfa-2b 3 MIU/m2 3 times a week
+ interferon alfa-2b 3 MIU/m2 triput na tjedan
+ Letrozole 2.5 mg /day
+ letrozol 2,5 mg /dan
+ OBR N=18
N=18
+ OBT
Placebo + OBT
+ Odds ratio and p-value were obtained from a logistic regression model adjusted for baseline ECOG Performance Score (0 versus 1).
+ Omjer šansi i p-vrijednosti dobiveni su modelom logističke regresije prilagođenim za početnu vrijednost općeg stanja bolesnika prema ECOG-u (0 naspram 1).
+ Patients randomised to liraglutide were initiated at a dose of 0.6 mg/day.
+ Bolesnici randomizirani za primanje liraglutida liječenje su započeli dozom od 0,6 mg/dan.
+ RBV† for 12
C-SALVAGE
+ RBV† for 8, 12, or 18 weeks (N=60, 152, and 65, respectively)
18 tjedana (N=60, 152 odnosno 65)
+ Ribavirin
+ Ribavirin Mylan
+ ribavirin (800-
IU triput na tjedan) + ribavirin (800
+ ribavirin 15 mg/kg/day
+ ribavirin 15 mg/kg na dan
+ ribavirin for 24 weeks and 2.4% for subjects receiving sofosbuvir + peginterferon alfa + ribavirin for 12 weeks.
12 tjedana, 0% među ispitanicima koji su primali sofosbuvir + ribavirin tijekom 16 tjedana, 11,1% među ispitanicima koji su primali peginterferon alfa + ribavirin tijekom 24 tjedna i 2,4% među ispitanicima koji su primali sofosbuvir + peginterferon alfa + ribavirin tijekom 12 tjedana.
+ Solvent:
+ Otapalo:
+ Solvent: 2 ml
+ Otapalo: 2 ml
+ Solvent: 5 ml (200 IU/ml)
Otapalo: 5 ml (200 IU/ml)
+ Solvent: 5 ml (400 IU/ml)
Otapalo: 5 ml (400 IU/ml)
+ Solvent: 5 ml (600 IU/ml)
Otapalo: 5 ml (600 IU/ml)
+ Supplementary dose is a single additional dose
+ Dopunska doza je jedna dodatna doza
+ Telithromycin is not active against organisms that constitutively express the MLSB resistance determinant (cMLSB).
+ Telitromicin nije djelotvoran protiv mikroorganizama s konstitutivnom ekspresijom odrednice rezistencije tipa MLSB (cMLSB).
+ Uncommon G3/4
+ manje često, stupanj 3/4
+ Varicella caused by vaccine strain was observed in post-marketing use with Varicella Vaccine live (Oka/Merck).
+ U razdoblju nakon stavljanja u promet živog cjepiva protiv varičele (Oka/Merck), opažene su varičele uzrokovane sojem iz cjepiva.
+ Viekirax without
kombinaciji s lijekom
+ With baseline observation carried forward (BOCF)
+ S početnim zapažanjem prenesenim dalje (BOCF)
++ Common G3/4
++ često, stupanj 3/4
++ Subjects who have a baseline and a post-baseline body weight measurement and completed 56 weeks (Studies NB-301, NB-302, and NB-304) or 28 weeks (NB-303) of treatment.
++ Ispitanici kojima je mjerena početna i tjelesna težina nakon početne i koji su završili liječenje od 56 tjedana (ispitivanja NB-301, NB-302, i NB-304) ili 28 tjedana (NB-303).
++ Subjects who have a baseline and a post-baseline body weight measurement and completed 56 weeks (Studies NB-301, NB-302, and NB-304) or 28 weeks (NB-303) of treatment.
++ Ispitanici kojima je mjerena početna i tjelesna težina nakon početne i završili su liječenje od 56 tjedana (ispitivanja NB-301, NB-302, i NB-304) ili 28 tjedana (NB-303).
+/- DMARDs N=159
+/- DMARD
+/- DMARDs N=162
+/- DMARD
+/- DMARDs N=167
+/- DMARD
+/- DMARDs N=168
+/- DMARD
+/- DMARDs N=169
+/- DMARD
+/- DMARDs N=496
+/- DMARD
+/- DMARDs N=497
+/- DMARD
+1 Hypotension
+1 hipotenzija
+1 Hypotension
vazodilatacija
+1.0 mg (all other patients)
+1,0 mg (svi drugi bolesnici)
+1.5 mg (female on oral oestrogen)
+1,5 mg (žene na peroralnim estrogenima)
+1Supraventricular tachyarrhythmia
+1supraventrikularna tahiaritmija
+2 NRTI N=242
+ 2 NRTI N=242
+20ml syringe
+štrcaljka od 20 ml +adapter
+39-02-21277220 e-mail: info@molmed.com
+39-02-21277220 e-pošta: info@molmed.com
+Acute pulmonary oedema
+akutni plućni edem
+Acute pulmonary oedema
edem pluća
+Acute respiratory distress syndrome
+akutni respiratorni distres sindrom
+Acute respiratory distress syndrome
intersticijska bolest pluća
+adaptor
1/1
+alopecia
+alopecija
+Anaemia,
+anemija,
+Anaphylactic reaction
+anafilaktička reakcija
+Anaphylactic shock
+anafilaktički šok
+angina,
+srčani poremećaj
+ASA
+ASK
+ASA (N = 1736)
+ASK (N = 1736)
+ASA (N = 1740)
+ASK (N = 1740)
+ASA (N = 4980)
+ASK (N = 4980)
+ASA (N = 6716)
+ASK (N = 6716)
+ASA (N = 6716)
Klopidogrel b +ASK (N = 6716)
+ASA (N = 6741)
+ASK (N = 6741)
+Bronchospasm
+bronhospazam
+cardiac disorder
+srčani poremećaj
+DMARDsb
+DMARD-ib
+DMARDsb n = 133
+DMARD-ib +DMARD-ib n = 256 n = 133
+DMARDsb n = 133
+DMARD-ib n = 133
+DMARDsb n = 256
+DMARD-ib n = 256
+Docetaxel N=107
+ docetaksel N=107
+Docetaxel)
+ docetaksel)
+Dyspnoea
+dispneja
+Embolism and thrombosis
+embolija i tromboza
+febrile
+febrilna
+Febrile Neutropenia
+febrilna neutropenija
+Febrile Neutropenia
depresija koštane srži, +febrilna neutropenija
+Hypoxia
+hipoksija
+Infection, Oral herpes
+infekcija, oralni herpes
+Lethargy, Temperature intolerance
+letargija, osjetljivost na promjene
+Lethargy, Temperature intolerance
+letargija, osjetljivost na promjene temperature okoline
+Leucopenia,
+leukopenija,
+Leucopenia, +Anaemia,
+anemija, +febrilna
+Leucopenia, +Anaemia,
+leukopenija, +anemija,
+Lung infiltration
+plućni infiltrat
+Lung infiltration
edem larinksa
+MTX
+ MTX
+MTX n = 214
+ MTX n = 214
+MTX n = 253
+ MTX n = 253
+myocardial
+infarkt miokarda4 i
+myocardial
+ishemija
+myocardial
Vrlo često
+myocardial infarction4 and 6,
+infarkt miokarda4 i
+Neutropenia,
+neutropenija,
+Neutropenia,
+neutropenija, +leukopenija,
+Neutropenic fever, Thrombocytopen ia
+febrilna neutropenija, trombocitopenija
+Neutropenic fever, Thrombocytopenia
+febrilna neutropenija,
+Neutropenic fever, Thrombocytopenia
+febrilna neutropenija, trombocitopenija
+Neutropenic fever, Thrombocytopenia
neutropenija, trombocitopenija
+Optimised backgrounda
+optimizirana osnovna terapijaa
+Other types of pegIFN/RBV failure include less well documented non-response, relapse/breakthrough or other pegIFN failure.
+Ostale vrste neuspjeha liječenja kombinacijom pegIFN/RBV uključuje manji precizno dokumentirani izostanak odgovora, relaps/proboj ili druge oblike neuspjeha liječenja kombinacijom pegIFN/RBV.
+Oxygen saturation decreased
+smanjena zasićenost kisikom
+pancytopenia,
+pancitopenija,
+Pleural effusion
+pleuralni izljev
+Pleural effusion
+respiratorni distres
+Pneumonia
+pneumonija
+Pneumonia
plućni poremećaj
+Pulmonary fibrosis
+akutni plućni edem
+Pulmonary fibrosis
+plućna fibroza
+Respiratory distress
+akutni respiratorni distres sindrom
+Respiratory distress
+respiratorni distres
+Respiratory failure
+hipoksija
+Respiratory failure
+zatajenje dišnog sustava
+TCH N=77
+ TCH N=77
+thrombocyt
+trombocitopenija
+ventricular
+ventrikularna
, avenue Edouard Belin 92500 Rueil-Malmaison France
1-15, avenue Edouard Belin 92500 Rueil-Malmaison Francuska
, Connective Tissue and Bone Disorders
koštanog sustava i vezivnog tkiva
, Connective Tissue and Bone Disorders
mišićno- koštanog sustava i vezivnog tkiva
, connective tissue and bone disorders
Opći poremećaji i reakcije na mjestu primjene
, Guillain-Barre syndrome, nystagmus
jetrena encefalopatija, Guillain- Barréov sindrom, nistagmus
, interstitial nephritis (kidney inflamation), haematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination)
nefrolitijaza (stvaranje bubrežnih kamenaca), intersticijalni nefritis (upala bubrega), hematurija (krv u mokraći), proteinurija (višak proteina u mokraći), polakizurija (učestalo mokrenje)
, myalgia, arthralgia, joint disorder, bone pain
mišićima, bol u zglobovima, poremećaj zglobova, bol u kostima
. Al3+ (as hydroxide) 2.7 mg
. Al3+ (kao hidroksid) 2,7 mg
. Each pack contains 3 pre-filled syringes of 0.3 ml and 3 needles
Jedno pakiranje sadrži 3 napunjene štrcaljke s 0,3 ml otopine i 3 igle
. If you have any questions or concerns about the safe disposal of these materials, please talk to your doctor, pharmacist or nurse.
U slučaju bilo kakvih pitanja ili zabrinutosti u vezi sa sigurnim odlaganjem ovih materijala, obratite se svom liječniku, ljekarniku ili medicinskoj sestri.
. No treatment experience is available for this subpopulation of patients, and therefore the use of Pradaxa is not recommended in this population (see sections 4.4 and 5.2).
Ne postoji iskustvo u liječenju ove podskupine bolesnika te se stoga primjena Pradaxe ne preporučuje u ovoj skupini (vidjeti dijelove 4.4 i 5.2).
. The PAC – which is inserted inside the carton box - must include the following key messages (see also annex IIIA):
Kartica s upozorenjima za bolesnika – koja je stavljena u kutiju lijeka – mora sadržavati sljedeće ključne poruke (vidjeti i Dodatak IIIA):
. The safety and efficacy of Levemir in children below the age of 1 year have not been established.
Sigurnost i djelotvornost lijeka Levemir u djece mlađe od 1 godine nisu ustanovljene.
................................................................................................................................................per 0.2 ml dose
................................................................................................................................................po 0,2 ml doze
.......................................................................................................per 0.2 ml dose
............................................................................................................................po dozi od 0,2 ml
.Adverse reactions are listed in Table 1 below.
Nuspojave su navedene u Tablici 1 dalje u tekstu.
.Cumulative doses of greater than 5 mg/kg should not be administered within 24 hours.
Tijekom 24 sata ne smije se primijeniti kumulativna doza viša od 5 mg/kg.
.gE deleted inactivated IBR virus, at least ............................................................................
.gE deletirani inaktivirani ZRG virus, najmanje ...................................................................
.If you get any side effects, talk to your doctor or pharmacist.
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
.Inactivated Bluetongue Virus Serotype 1............................................................... 1.9 log10 pixels * (*) Antigen content (VP2 protein) by immuno-assay
Inaktivirani Virus protiv bolesti plavog jezika Serotip 1 ....................................... 1,9 log10piksela * (*) Antigen sadržaj (VP2 proteina) po imuno-testu
.Tafinlar is taken at least one hour before or two hours after a meal.
Tafinlar se uzima barem jedan sat prije ili dva sata poslije obroka.
/ 22 micrograms
/ 22 mikrograma
/ naloxone
nalokson
/ Preferred Term
/ preporučeni izraz
/ ritonavir 700 mg/100 mg
/ ritonavirom 700 mg/100 mg 2
/12 micrograms.
340 mikrograma/12 mikrograma.
/hypertension (2.1% / 0.8%).
/hipertenzija (2,1%/0,8%).
/lamivudine
/lamivudin
/mL):
100 000
/ritonavir
(0,89-0,98)
/ritonavir
1,21
/ritonavir
aritaprevir/ri
/ritonavir
tonavir.
/ritonavir with or without ribavirin.
/ritonavirom, s ribavirinom ili bez njega.
0 - 12 months
0 – 12 mjeseci
0 - 12 months
> 3 mjeseca do 12 mjeseci
0 - 30 min
0 – 30 min
0 - 30 min 0.5 mL/min
0 – 30 min
0 180 360 540 720
Br. izloženih riziku
0 days
0 dana
0 weeks
Tjedan 0
0 – 120 hours
0 – 120 sati
0 – 24 hours
0 – 24 sata
0% (0/25)
FCH
0% (0/4)
Ciroza
0% (2.0-2.4 mEq/l)
0% (2,0-2,4 mEq/l)
0% (> 3.4 x ULN)
0% (> 3,4 x GGN)
0%), cytolytic hepatitis (0.3% vs 0%), hepatomegaly (0.5% vs 0.2%)
prema 0%), citolitički hepatitis (0,3% prema 0%), hepatomegalija (0,5% prema 0,2%)
0%), stomatitis (0.2% vs 0.2%), constipation (0.3% vs
prema 0%), stomatitis (0,2% prema 0,2%), konstipacija (0,3% prema 0,5%), abdominalna distenzija (0,7
0, 1, 2, 12 months: three injections with an interval of one month; a fourth dose should be administered at 12 months.
0., 1., 2., 12. mjesec: tri injekcije u vremenskom razmaku od jednog mjeseca; četvrta doza treba se primijeniti 12 mjeseci nakon prve injekcije.
0, 2 months
0, 2 mjeseca
0, 21 days schedule (D-Pan-H5N1-002)
režim 0, 21 dan (D-Pan-H5N1-002)
0, 6 months
0, 6 mjeseci
0, light peach opaque cap and white opaque body, hard-shell gelatin capsule filled with white to off-white powder.
0 sa svjetloružičastom neprozirnom kapicom i bijelim neprozirnim tijelom napunjena bjeličastim prahom.
0-120 hours
0 – 120 sati
0-24 hours
0 – 24 sata
0-26 weeks
0-26 tjedana
0-26 weeks
0-26 tjedna
0-3 years
0-3 godina
0-4 HDDc
0-4 DTPPc
0-52 weeks
0-52 tjedna
0-8 hours
preporučuje.
0.0
(N=473)
0.0001g
NS 0,0001g
0.0002i
0,0002i
0.0007
n.p.
0.0007 (0.0002 – 34)c
0,0007 (0,0002-34)c
0.002-0.006c
0,002-0,006c
0.0020
čvorova
0.0030 (vs Perjeta+ Trastuzumab+ Docetaxel)
0,0030 (naspram Perjeta + trastuzumab + docetaksel)
0.0031
mokraćni mjehur
0.005 (0.003 – 0.009)a
0,005 (0,003-0,009)a
0.005-0.016c
0,005-0,016c
0.007 to 0.075 μM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.007 to 1.5 μM).
HIV-2 (vrijednosti EC50 bile su u rasponu od 0,007 do 1,5 µM).
0.008
Placebo)
0.009 (0.005 – 0.01)b
0,009 (0,005-0,01)b
0.011b
265 (62)
0.01b
N/Pc
0.02 % and 3.4 % in Prevotella intermedia isolates.
S. pseudintermedius i beta-hemolitičkih streptokoka bila je manja od 0,02%, odnosno 3,4% u izolatima Prevotelle intermedije.
0.02 mg daily + Victrelis 800 mg
0,02 mg na dan + Victrelis 800 mg
0.02 mg/l for an average of 8 months, however, in some patients it may take up to 2 years to reach plasma concentration below 0.02 mg/l.
0,02 mg/l tijekom prosječno 8 mjeseci, iako u pojedinih bolesnika može biti potrebno i do 2 godine kako bi se koncentracija lijeka u plazmi spustila ispod 0,02 mg/l.
0.02 microgram/ml (range 0 to 0.054) within 1 to 3 days after a 2 mg intravitreal injection, and were undetectable two weeks following dosage in almost all patients.
3 dana nakon intravitrealne injekcije 2 mg, a dva tjedna nakon primjene doze nije se mogla otkriti gotovo niti u jednog bolesnika.
0.020b
19,1; 27,2
0.021-0.054d
0,021-0,054d
0.025 - 0.035 mg/kg bodyweight given as a daily subcutaneous injection.
0,025 – 0,035 mg/kg tjelesne težine supkutanom injekcijom jednom na dan.
0.025 - 0.035 mg/kg bodyweight injected each day under the skin (subcutaneous injection).
0,025 – 0,035 mg/kg tjelesne težine ubrizgano potkožno svaki dan (supkutana injekcija).
0.025 mg)/ sofosbuvir (400 mg once daily)d
0,025 mg)/sofosbuvir (400 mg jedanput na dan)d
0.025 mg)/ velpatasvir (100 mg once daily)d
0,025 mg)/velpatasvir (100 mg jedanput na dan)d
0.025–0.035 mg/kg body weight per day or 0.7–1.0 mg/m2 body surface area per day.
0,025-0,035 mg/kg tjelesne težine na dan ili 0,7-1,0 mg/m2 površine tijela na dan.
0.027
Karcinom
0.03 mg/levonorgestrel 0.15 mg) 1 hour before or 11 hours after 10 mcg lixisenatide, the Cmax, AUC, t1/2 and tmax of ethinylestradiol and levonorgestrel were unchanged.
0,03 mg/levonorgestrel 0,15 mg) 1 sat prije ili 11 sati nakon primjene 10 µg liksisenatida, Cmax, AUC, t1/2 i tmax etinilestradiola i levonorgestrela ostali su nepromijenjeni.
0.032% (v/v)
0,032% (v/v)
0.035 mg once daily
0,035 mg jedanput